From: Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis
Group | Mean | Std. Deviation | Paired t | P | |
---|---|---|---|---|---|
Group1 | FVC (ml) | 1287.6000 | 106.79760 | − 0.990 | 0.3125 |
FVC (ml) 6M | 1265.5530 | 215.15587 | |||
FVC%predicted | 55.7500 | 4.26584 | 0.340 | 0.814 | |
FVC%predicted 6M | 53.8500 | 6.42589 | |||
6MWT (m) | 287.5000 | 33.06692 | 1.785 | 0.0674 | |
6MWT (m) 6M | 310.0000 | 74.09809 | |||
PaO2 at rest | 64.7500 | 2.31414 | − 1.653 | 0.0881 | |
PaO2 at rest 6M | 66.0500 | 2.81864 | |||
SaO2 | 93.5000 | 2.48151 | 1.245 | 0.124 | |
SaO2 6M | 94.1500 | 3.52846 | |||
PAP | 35.0000 | 7.36278 | 1.085 | 0.231 | |
PAP 6M | 33.0000 | 6.56947 | |||
SGRQ SCORE | 37.2000 | 1.43637 | 1.106 | 0.224 | |
SGRQ SCORE 6M | 38.2500 | 2.35123 | |||
Group2 | FVC (ml) | 1276.0000 | 106.74120 | 4.745 | 0.00** |
FVC (ml) 6M | 1100.5000 | 109.46160 | |||
FVC%predicted | 57.4500 | 6.16542 | 1.879 | 0.052 | |
FVC%predicted 6M | 48.5000 | 4.53640 | |||
6MWT | 290.0000 | 28.83711 | 4.314 | 0.00** | |
6MWT 6M | 267.0000 | 37.98892 | |||
PaO2 at rest | 62.8500 | 4.24605 | 3.088 | 0.002* | |
PaO2 at rest 6M | 54.9000 | 3.53777 | |||
SaO2 | 92.5000 | 2.65370 | − 5.139 | 0.00** | |
SaO2 6M | 87.0000 | 3.07794 | |||
PAP | 33.2500 | 5.74800 | − 2.019 | 0.048* | |
PAP 6M | 36.8000 | 5.95686 | |||
SGRQ SCORE | 37.8500 | 2.42441 | − 3.795 | 0.00** | |
SGRQ SCORE 6M | 44.5000 | 2.35627 |